IP Library Granted Patent US 10,683,492
Granted Patent B2
US 10,683,492 · App. 14/896,763 · Granted Jun 16, 2020

Transgenic factor VII having a specific N-glycosylation and substantially homogenous isoelectric point

Inventor: Guillaume Chevreux (Paris, FR)
Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
C12N9/6437A01K67/0275A01K67/0276A61K38/36C07K14/745A01K2217/052A01K2227/107A01K2267/02A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,492
App. No.
14/896,763
Granted
Jun 16, 2020
Kind
B2
Abstract

The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.

Claims (12)

1. A composition comprising factor VII molecules having a substantially homogeneous isoelectric point,

wherein among all N-glycan forms of the factor VII molecules, between 70% and 80% of the N-glycan forms are monocharged and between 15% and 25% of the N-glycan forms are bicharged,

wherein at least 80% of the factor VII molecules have γ-carboxylation on 9 residues of glutamic acid, and

wherein the factor VII originated from transgenic rabbits produced by microinjection of an expression vector comprising a beta-globin insulating sequence from chicken, a control region of goat beta-casein at 5′, an optimized cDNA sequence for expression in mammal cells coding for human FVII, and a non-translated region of beta-casein at 3.

2. The composition according to claim 1 , wherein among all the factor VII molecules of the composition, at least 85% of said molecules have γ-carboxylation on 9 residues of glutamic acid.

3. The composition according to claim 2 , wherein the γ-carboxylation level present on the residue of glutamic acid 35 (Glu35) is less than 20%.

4. The composition according to claim 1 , wherein at least 60% of N-glycan forms of the factor VII molecules are mono sialylated complexes.

5. The composition according to claim 1 , wherein at least 25% of the N-glycan forms of the factor VII of the composition are high Mannose/hybrid.

6. The composition according to claim 1 , wherein at least 95% of the factor VII molecules of the composition have an isoelectric point in a pH unit interval of less than 1.2.

7. The composition according to claim 1 , wherein at least 50% of the factor VII molecules of the composition have an isoelectric point in a pH unit interval of less than 0.5.

8. The composition according to claim 7 , wherein at least 60% of the factor VII molecules of the composition have an isoelectric point in a pH unit interval of less than 0.4.

9. The composition according to claim 1 , wherein the factor VII is an activated factor VII.

Assignments (3)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2016
From: CHEVREUX, GUILLAUME
To: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 037774/0629 →
Priority Claims (1)
FR 13 55403 · Jun 11, 2013 · national
Continuity (1)
Related Publication 20160152965A1 · Jun 2, 2016